Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
about
Recent advances in oral vaccine development: yeast-derived β-glucan particlesCochleates derived from Vibrio cholerae O1 proteoliposomes: the impact of structure transformation on mucosal immunisationVaccines: the Fourth CenturyCAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferretsMucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motilityIntranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trialVibrio cholerae: lessons for mucosal vaccine design.Formulation and evaluation of oral microparticulate ovarian cancer vaccines.Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.Archaeal lipid mucosal vaccine adjuvant and delivery system.Topical and mucosal liposomes for vaccine delivery.Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective.Delivery of antigens used for vaccination: recent advances and challenges.Optimizing efficacy of mucosal vaccines.Current state and challenges in developing oral vaccines.Oral delivery of particulate prostate cancer vaccine: in vitro and in vivo evaluation.Mucosal and systemic immune responses induced by a single time vaccination strategy in mice.Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.
P2860
Q27001699-E6A81DEB-5CAD-4D28-B6F0-8FBFBEE7FC74Q27316184-65AFD6C5-CED1-45B6-A626-6497B5B8CC49Q27490454-633F1C30-9EAB-4F94-A16D-21C35DA00EC1Q28741710-671F5F78-C4CD-4A31-8243-8264D154F2D8Q30496874-A8C5300E-28F5-42D6-8EC5-E35956076F19Q34513477-0D217F75-23BC-4D36-BC32-33E2928D6793Q34562952-EA8AD751-9DEB-4689-875A-CDC768797F83Q36212696-0CDC8207-844C-4592-A035-DAC26AE5A80AQ36970778-0CCFF88B-ECBB-447C-AD8C-72186374A2DDQ37371036-3774001D-B028-4B7C-BDC7-650393678A45Q37719553-D8A3FDD2-BD7A-493F-9F2A-20520AB3542AQ37724863-C652EDB9-D38F-4BF4-8859-613E34A5BE91Q37848296-5D8A59DF-9A0C-4C7C-88B0-24A33D7A71FDQ38013202-47EB1EF2-2C7B-405A-BCF4-98060BC9C8E4Q38020309-6D361FE8-5A10-4266-A76D-F08C7DABBB7AQ38028969-367555A2-1084-4566-A34F-5103C2C80BDFQ38059754-37D3D96C-F288-47C0-9F85-D0AA3845A4A0Q39259629-E5252B3A-7D5D-488B-8603-25C580FCF97FQ39403174-BE25C30E-6C93-40AC-8DAC-BE10714D44A9Q41125196-CF26B297-0835-449D-99FE-5EAC1DC6E423Q42117985-B8F8A2F0-6AE4-4659-AAAB-532D1C1B2EEB
P2860
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@en
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@nl
type
label
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@en
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@nl
prefLabel
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@en
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@nl
P2093
P2860
P356
P1476
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
@en
P2093
Jamie F S Mann
Judith Del Campo
Oliver Pérez
Reinaldo Acevedo
P2860
P304
P356
10.1586/14760584.8.1.103
P577
2009-01-01T00:00:00Z